

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07H 21/00, 21/02, C12N 15/10, C12P 19/34</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/09313</b> <b>(43) International Publication Date:</b> 28 March 1996 (28.03.96)
<b>(21) International Application Number:</b> PCT/US95/11831 <b>(22) International Filing Date:</b> 18 September 1995 (18.09.95)  <b>(30) Priority Data:</b> 08/308,280 19 September 1994 (19.09.94) US  <b>(71) Applicant:</b> PROMEGA CORPORATION [US/US]; 2800 Woods Hollow Road, Madison, WI 53711-5399 (US).  <b>(72) Inventor:</b> EKENBERG, Steven, J.; 1117 Perry Center Road, Mount Horeb, WI 53572 (US).  <b>(74) Agents:</b> FRENCHICK, Grady, J. et al.; Stroud, Stroud, Willink, Thompson & Howard, Suite 300, 25 West Main Street, P.O. Box 2236, Madison, WI 53701-2236 (US).		<b>(81) Designated States:</b> AU, CA, FI, JP, NO, NZ, PL, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> A METHOD FOR PURIFYING mRNA USING COLLOIDAL MAGNETIC PARTICLES  <b>(57) Abstract</b>  A method for purifying mRNA comprising 1) lysing the cells in guanidine isothiocyanate, 2) hybridizing the mRNA to a biotinylated oligo dT probe, 3) adding blocking or masking particles which agglomerate in high salt, 4) centrifuging the mixture, 5) adding colloidal magnetic particles coated with streptavidin, and 5) removing the double-stranded nucleic acid bound to the magnetic particles by inserting a magnetic probe into the lysate solution. This process allows for controllably creating agglomerates from particles of colloidal dimensions.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TC	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

A METHOD FOR  
PURIFYING mRNA USING COLLOIDAL MAGNETIC PARTICLES

Inventor(s): Steven J. Ekenberg

Cross Reference to Related Application

5           Reference is made to commonly assigned, concurrently filed applications Serial No. \_\_\_\_\_, entitled "Multisample Magnetic Separation Device", and to Serial No. \_\_\_\_\_, entitled "High Efficiency Method For Isolating Target Substances Using a Multisample Separation Device", which applications are incorporated by reference  
10           herein in their entirety.

**TECHNICAL FIELD**

          The present invention relates to processes for creating agglomerates, "flocs", or coagulants from particles of colloidal dimension or size. In one aspect, the present invention relates to  
15           methods or processes for separating or isolating target substances from other media. This invention is particularly applicable where small amounts of starting material(s) are to be processed. More specifically, the present invention relates to methods of separating or isolating a target substance or substances, or a complex from other media,  
20           especially where a multisample, preferably magnetic, separation device is utilized. Yet more specifically, this invention relates to methods for providing a physical separation or barrier layer between, e.g., a biological target substance or substances and interfering species, such as biological debris. In yet a further aspect, the present invention  
25           relates to the utilization of chaotropic species (i.e., chaos-forming species) to separate a colloidal suspension.

          In a broader sense, aspects of this invention are applicable to any situation where a suspension or a solution of a target material is to be

-2-

physically separated from an interfering substance or substances which can be collected or localized, e.g., by centrifugation. This invention provides the means by which the step of separating a target material from an interfering substance, e.g., by transfer of one away from the other via pipette or other means, can be completely avoided.

The concomitant of this invention is that where interfering substances can be localized, e.g., by centrifugation, subsequent processing of the target particles or target substance solution/suspension can be accomplished in the same centrifuge sample well.

#### BACKGROUND OF THE INVENTION

Colloidal particles are defined to be particles having a major dimension in the range of 1 millimicron to about 1 micron. Colloidal particles may be gaseous, liquid, or solid and occur in various types of suspensions. For example, colloidal particles may occur in solid-gas suspensions (aerosols), solid-solid suspensions, liquid-liquid suspensions (emulsions), and gas-liquid suspensions (foam). Generally speaking, colloidal particles have a surface area that is so large with respect to their volume that the particles do not settle out of the suspension by gravity. Further, the particles are small enough to pass through filter membranes. Macromolecules, i.e., proteins and other high polymers, are usually thought to be at the lower limit of the above range for particles of colloidal dimension. In terms of the present invention, "colloidal particles" is intended to include organic and inorganic particles of the indicated dimension.

Techniques for causing colloidal particles to come out of suspension have been found to be very useful in the separation or isolation of biological target substances from unwanted or interfering species. The present invention is a method of causing colloidal particles to come out of suspension under controlled conditions so as to create a physical barrier, layer, or "pill".

-3-

This invention solves a particular problem which sometimes occurs during the formation of biological complexes such as receptor/ligand complexes or in the separation of such receptor/ligand complexes from the medium in which they are dispersed. Specifically, it was found that, in the isolation of mRNA, after cell disruption or homogenation, dilution and centrifugation to generate cleared cell lysates, the precipitated proteins and cellular debris in the end of the centrifuge tube (usually in the form of a pellet) would interfere with complex formation between magnetic streptavidin particles and biotinylated oligo (dT):mRNA complexes. The specific interference caused by the unwanted proteins and cellular debris was interference in the release of mRNA from magnetic streptavidin particles upon addition of distilled water to collected streptavidin particles having biotinylated oligo (dT):mRNA complexes thereon. This invention solves the above problem.

However, this invention is broadly applicable to any circumstance where a target substance is to be isolated from a medium and physical separation from interfering materials is desired. In the context of a biological target substance, this invention provides enhanced reproducibility, even where small or very small samples are involved, by reducing sample loss. A specific, preferred application of this invention where a multiple well plate is used in a magnetic separation process is that described in applicants' commonly assigned and concurrently filed patent application referred to above.

25

### SUMMARY OF THE INVENTION

Briefly, in one aspect, the present invention is a method of agglomerating colloidal particles in an aqueous medium utilizing a chaotropic species or chaotropic agent. The present method includes the steps of first providing a quantity of particles of colloidal dimension in an aqueous medium.

30

-4-

Next, a chaotropic agent, e.g., guanidine thiocyanate (GTC) extraction buffer and a dilution buffer are provided. The dilution buffer preferably comprises tris-HCl, SSC (i.e., sodium chloride/sodium citrate buffer), sodium dodecyl sulfate, and EDTA. The GTC buffer, the dilution buffer, and the colloidal particles are mixed, causing the colloidal particles to agglomerate or accumulate into substantially larger particles or agglomerates. The substantially larger particles are no longer of colloidal dimension and can be centrifuged into a layer with ease. Generally speaking, the GTC extraction buffer comprises guanidine thiocyanate (4M), sodium citrate (.025M), and 2% beta-mercaptoethanol (BME).

In a related aspect, the present invention is a method for isolating or detecting (or both) a target substance of biological interest from interfering biological debris, especially where a multi-well separation device is employed. Biological target substances in the present invention are collected by the formation of a complex with a second substance, the complex having properties which permit it to be separated from the medium in which it is dispersed by application of an external influence such as electric field, magnetic field, U.V., visible or infrared radiation or temperature change.

"Chaotropic species" or "chaotropic" agents, as those terms are used herein, are to be broadly construed to mean any chaos-forming or chaos-enhancing entities. Without being limited to a theory, chaotropic agents are believed to act by interfering with the hydrogen bond structure of regular water.

Destruction of water structure decreases what is known as hydrophobic effect which tends to promote the unfolding and possible dissociation of, e.g., protein molecules.

As applicable to the present invention, the chaotropic agent reduces the normally ordered water structure and thereby permits the colloidal particles to approach each other more closely. During closer



-5-

5 approach, the colloidal particles tend to collect or agglomerate, i.e., to come out of suspension. When this happens, the particle collection achieves a larger size and can be controllably deposited, e.g., by centrifugation or filtration to create a physical barrier in a separation/isolation process.

Chaotropic salts are salts of chaotropic ions. The salts are highly soluble in aqueous solutions. The chaotropic ions provided by such salts, at sufficiently high concentration in aqueous solutions of proteins or nucleic acids, cause proteins to unfold, nucleic acids to lose  
10 secondary structure or, in the case of double-stranded nucleic acids, to melt (i.e., strand-separate). Chaotropic ions include guanidinium, iodide, perchlorate and trichloroacetate. Preferred in the present invention is the guanidinium ion. Chaotropic salts include guanidinium chloride, guanidinium thiocyanate (which is sometimes referred to as guanidinium  
15 isothiocyanate), sodium iodide, sodium perchlorate, and sodium trichloroacetate. Preferred are the guanidinium salts.

With any chaotropic agent or salt used in the invention, it is desirable that the concentration of the salt, in any of the solutions in which the salt is employed in carrying out the invention, remain below  
20 the solubility of the salt in the solution under all of the conditions to which the solution is subjected in carrying out the invention.

In a preferred practice of the present invention, the target substance interacts with a magnetically responsive second particle to form a complex which may be separated from the biologic medium by  
25 application of magnetic separation techniques. While this invention is specifically disclosed with reference to magnetic separation techniques, other techniques such as application of electrical energy, e.g., repulsion/attraction, irradiation, or chemical interaction and the like, may be employed.

30 As used herein, the term "target substance" or "target particle" refers to any member of a specific binding pair, i.e., a pair of substances

-6-

or a substance and a structure exhibiting a mutual affinity of interaction and includes such things as cell components, biospecific ligands and receptors.

5 "Ligand" is used herein to refer to substances, such as biotin, antigens, haptens, proteins, nucleic acids and various cell-associated structures, having at least one characteristic determinant or epitope, which are capable of being biospecifically recognized by and bound to a receptor.

10 "Receptor" is used herein to refer to any substance or group of substances having a biospecific binding affinity for a given ligand, to the substantial exclusion of other substances. Among the receptors determinable via biospecific affinity reactions are biotin-binding proteins (e.g., avidin and streptavidin), antibodies (both polyclonal and monoclonal), antibody fragments, enzymes, proteins, nucleic acids, and  
15 the like. The determination of any member of a biospecific binding pair is dependent upon its selective interaction with the other member of the pair.

As used herein, the term "magnetic" is meant to refer to permanently and temporarily magnetic materials, and to magnetically  
20 responsive materials, i.e., materials capable of being magnetized in the presence of a magnetic field but which are not themselves magnetic in the absence of such a field, such as paramagnetic materials.

### BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a perspective schematic illustration of a microcentrifuge  
25 tube or well utilizing the present invention.

### DETAILED DESCRIPTION

As is described above, this invention is preferably utilized with magnetic separation devices for separation of magnetic particles from nonmagnetic media utilizing a multi-well or multi-titer separation device.



-7-

While a 96-well separation device is disclosed, a separator with five or more wells can be used more effectively in a practice of this invention. The present invention is particularly well-suited for use in separating biological substances of interest in various laboratory and clinical procedures involving biospecific affinity reactions. Accordingly, the present invention will now be described in detail with respect to such endeavors. However, those skilled in the art will appreciate that such a description of the invention is meant to be exemplary only and should not be viewed as limitative of the full scope thereof.

A preferred method in accordance with the present invention utilizes particles which are magnetically responsive and which comprise a receptor capable of binding the substance of interest in the test sample. After the receptor binds the target substance, a magnetic separator can be used to remove the magnetic particles bound to the substance of interest from the test medium.

Biospecific affinity reactions may be employed in testing biological samples for the determination of a wide range of target substances. Representative target substances include cells, cell components, cell subpopulations (both eucaryotic and procaryotic), bacteria, parasites, antigens, proteins, specific antibodies, specific biological factors, such as vitamins, viruses and specific nucleic acid sequences, e.g., mRNA. Thus, the magnetic separation aspect of this invention has application in cell separations for the analysis or isolation of cells including, by way of example: T-cells from a T-cell lymphoma cell line; B-cells from a B-cell lymphoma cell line; CD4 positive cells from leukocytes; and lymphocytes from leukocytes.

The methods in accordance with the invention may also be used for immunospecific isolation of monocytes, granulocytes and other cell types; removal of rare cells; depletion of natural killer cells; determination of reticulocytes; and assays for neutrophil function, e.g.,

-8-

for determining changes in membrane potential, performing oxidative burst analysis, phagocytosis assays and opsonization studies.

Similarly, the magnetic separation aspect of the present method may be used in separation of pathogens, including but not limited to the separation of various bacteria and parasites from fecal matter, urine, sludges, slurries and water (e.g., ground water or streams). The present invention may also be used in separating various bacteria in food products (liquids to solids), sputum, blood, urine, body fluids, and homogenates of body fluids.

Magnetic particles may comprise paramagnetic materials such as, for example, metals (e.g., iron, nickel or cobalt), metal alloys (e.g., magnetic alloys of aluminum, nickel and cobalt) and metal oxides (e.g.,  $\text{Fe}_3\text{O}_4$  or  $\text{Fe}_2\text{O}_3$ ). The preferred material is the paramagnetic ferric oxide.

The paramagnetic particles may be provided with a nonmagnetic polymeric matrix or coating. Suitable materials are composed of a crystalline core of magnetically responsive material surrounded by molecules which may be physically absorbed or covalently attached to the magnetic core. For example, preferred are particles of an iron oxide core surrounded by receptor molecules or molecular probes depending on the type of ligand to be separated.

The preferred magnetic particles for use in carrying out this invention are particles having a size in the range of about 500 nm to about 2  $\mu\text{m}$ , i.e., noncolloidal particles that are subject to settling if undisturbed. Magnetic particles having the above-described properties are, for example, streptavidin-coated iron oxide paramagnetic particles which are commercially available from Promega Corporation, Madison, Wisconsin, U.S.A. under the trade designation Streptavidin MagneSphere® Paramagnetic Particles. Streptavidin MagneSphere® Paramagnetic Particles (SA-PMP's) are used in the magnetic separation or purification of various biotinylated molecules. Conversely, streptavidin may be separately purchased, e.g., from Promega Corporation, and

-9-

coated upon paramagnetic particles, e.g., those particles available from Advanced Magnetics, Cambridge, Massachusetts, U.S.A. In the context of this invention, mRNA may be isolated/separated.

For cell separations, the test medium is typically prepared from  
5 body fluids or tissues, such as blood, urine, sputum, secretions, or  
tissue samples. If magnetic separation is to be utilized, it is preferable  
to add the magnetic particles to the test medium in a buffer solution.  
A preferred buffer solution for, e.g., RNA isolations, is PolyATtract  
10 guanidine thiocyanate (GTC) Extraction Buffer containing  
 $\beta$ -mercaptoethanol commercially available from Promega Corporation,  
Madison, Wisconsin, U.S.A. The buffer solution should be isotonic, with  
a pH of about 7. The target substance may be added to the test  
medium before, after or simultaneously with introduction of the blocking  
15 particles. However, for hybridization assays, e.g., mRNA purification,  
it has been found that the magnetic particles are suitably added to the  
target substance after the hybridization reaction occurs and after  
blocking or masking of the cellular debris, according to one aspect of  
this invention. The test medium is usually incubated to promote binding  
between the receptor and any ligand of interest present therein.  
20 Incubation is typically conducted at room temperature, at a temperature  
slightly above the freezing point of the test medium (i.e., 4°C.) or even  
at elevated temperatures (e.g., 70°C.). The period of incubation is  
normally of short duration (i.e., about 1 to about 15 minutes). The test  
medium may be agitated or stirred during the incubation period to  
25 facilitate contact between receptor and ligand.

After binding of the receptor to the substance of interest is  
allowed to occur, magnetic separation of the magnetic particles from the  
test medium is performed in accordance with the above-cited co-pending  
application.

30 One of the advantages of the present invention is that, in one  
practice, a target substance such as mRNA, can be hybridized in

-10-

5 solution to the biotinylated oligo (dT) probe, rather than to a probe directly coupled to paramagnetic particles. This permits the user to achieve the combined speed and efficiency of solution hybridization with the convenience and speed of magnetic separation. The Streptavidin  
10 Paramagnetic Particles, SA-PMP (especially the MagneSphere® particles available from Promega Corporation), exhibit a high binding capacity for biotinylated oligonucleotides and very low nonspecific binding of nucleic acids. While the binding capacity of the SA-PMP varies with the specific oligonucleotide probe used for biotinylated oligo(dT), the binding capacity is approximately 1 nmol of free probe captured per mg of SA-PMPs.

15 The method of this invention utilizes "blocking" or "masking" particles to reduce or eliminate interference in the formation of magnetic complexes by cellular debris and precipitated proteins. The preferred blocking particles used in this invention are carboxylated, polystyrene, latex (especially fluorescent labeled yellow versions), 0.043  $\mu\text{m}$  particles, commercially available from Magsphere, Inc. of Pasadena, California, U.S.A. The blocking particles are added in sufficient quantity so as to cover, layer over, encase, encapsulate, or create a barrier over  
20 cellular debris which tends to be located in the extreme end of a centrifuge tube following centrifugation. The blocking particles generally are used in the isolation process between the steps of homogenation of the biological source containing the target particles and centrifugation of the homogenized medium to generate cleared lysate containing target  
25 particles.

In other words, blocking or masking particles are utilized in the isolation method after hybridization of mRNA and biotinylated oligo (dT) probe and before a biospecific affinity reaction is run. In the above-described, preferred description of the invention, after the above steps,  
30 SA-PMPs are added to the cleared lysate to generate a magnetically-

-11-

responsive complex with the mRNA target particles which can then be magnetically isolated.

5 The use of multi-well, magnetic separation techniques suggests several of the criteria which must be considered when selecting blocking or masking particles for utilization of this invention where other, non-magnetic, separation techniques are to be employed.

10 Of primary importance, the blocking or masking particles chosen should not, themselves, interfere with intended complex formation. In the context of the preferred practice of this invention, carboxylated 0.04  $\mu\text{m}$  polystyrene particles do not interfere with complex formation between mRNA target particles and paramagnetic streptavidin particles. If other target particle/ligand interactions, e.g., chemical bonding, hydrogen bonding, electro-repulsion, irradiation, electro-attraction, physical restraint (e.g., molecular sieve), are used to create complexes, 15 the blocking particles selected must not interfere with that complex formation.

Also to be considered is that the blocking or masking particles chosen should be of a size, density, chemical composition, or surface configuration or chemical characteristics so that they will agglomerate, 20 accumulate or otherwise associate to form a protective layer or coat over unwanted, interfering debris in, e.g., a centrifugation step. In this manner, interference with complex formation is minimized or eliminated because a physical separator, or a barrier layer between the debris (i.e., cell lysate solids) and cleared lysate or medium containing target particles is provided. The preferred blocking particles, under the 25 conditions described below, have been found to increase substantially in apparent volume. This feature tends to make them particularly attractive for utilization in the present invention.

30 Further, the masking or blocking particles should interact with each other in a compacting, aggregating, or associating manner, e.g., in response to the gravitational forces generated during centrifugation, to



-12-

create a layer, encasing, or coating which is substantially impermeable to the contained or "trapped" interfering debris. It is the trapping or localization of potentially interfering debris by utilization of blocking particles which provides the many advantages of this invention discussed above.

The utilization of masking or blocking particles provides a further unexpected advantage which is particularly applicable to multi-well separation systems, especially if automated systems are contemplated. The quantity of blocking particles can be used to adjust the volume relationship between cleared lysate and debris generated in centrifugation. Since the particles occupy part of the volume, e.g., of a Microtiter™ well (Microtiter is a trademark of Dynal, Inc., Lake Success, New York, U.S.A), their quantity may be adjusted to control precisely liquid levels within each well. In one application of this invention, the volume of colloidal particles added to the system during the isolation process is substantially less than volume of agglomerate produced therefrom. This results in amplification of the colloid particles volume, thereby enhancing the utility of this invention for use in liquid level adjustment.

In other words, in an aspect of this invention, liquid levels within an individual well can be controlled without the need to change the quantity of potentially scarce biological starting material containing target particles. Where magnetic pin separators which are dipped into an array of wells are used (e.g., those described in the concurrently filed application incorporated by reference above), the ability to control liquid levels within the system, in a cost-effective manner, may be very useful.

One skilled in this art will be able to select appropriate blocking particles or materials in light of the above teaching and of the isolation process employed. Substantially chemically inert, non-magnetic, colloidal, polyolefinic particles of the above-discussed size to work well if magnetic separation is employed. Other classes of particles could



-13-

include ceramic materials, molecular sieves, carbon particles, electrically conductive or non-conductive particles of all chemistries, polymeric or polymerizable particles of other types, latexes, diatomaceous earth, non-soluble powders, glycerol, polyethylene glycol polyethers (PEG),  
5 acrylamide particles, agaroses, and the like.

The following examples further describe in detail the manner and process of making and using the present invention. The examples are to be considered as illustrative but not as limiting of this invention. All temperatures given in the examples are in degrees Celsius, unless  
10 otherwise indicated.

#### Example 1

As is noted above, the present invention is particularly applicable to situations where a multiple well magnetic separation device is employed. For example, mRNA can be isolated in parallel from 48, 96  
15 (or more) tissue or cell samples and converted into first strand cDNA in approximately 2.5 hours (excluding sample preparation). A separator having a well array of five or more wells is generally what is intended by the terminology of "multiple well" as used herein. Polymerase chain reaction (PCR) processes may be performed on the cDNA in the same  
20 time period with no further sample preparation.

In this example of the present invention, high capacity streptavidin paramagnetic particles (SA-PMP), biotinylated oligo (dT), a 96 pin magnetic separator, and non-magnetic blocking particles were employed. First strand cDNA then was synthesized by the simple addition of  
25 M-MLV (H-) Reverse Transcriptase reaction mixture directly to the multiple well plate. The cDNA thereby generated was generally more stable than RNA and can be directly stored in the 96 well plate. Because an entire mRNA population is represented in each sample, the cDNA can be probed for multiple genes from the same tissue or cell  
30 sample. Further, by utilization of a multiple well microtiter plate,

-14-

samples may be processed in parallel, thereby facilitating direct comparison between identical samples exposed to differing process conditions.

5 A typical kit for practicing the present invention with, e.g., a 96 well plate magnetic separation device, has the following components:

- 10 • 30,000u M-MLV (H-) Reverse Transcriptase, 200u/ $\mu$ l
- 3ml RT 9600 Gold Buffer
- 50 $\mu$ l dNTP Mix, 10mM of each dNTP
- 175 $\mu$ g Oligo(dT)<sub>15</sub> Primer, 500 $\mu$ g/ml
- 10,000u rRNasin<sup>®</sup> Ribonuclease Inhibitor, 40u/ $\mu$ l
- 80 $\mu$ l Mouse Liver Lysate, 125 $\mu$ g/ $\mu$ l

The above-listed components are sometimes referred to as the cDNA Master Mix.

- 15 • 120ml PolyATtract<sup>®</sup> GTC Extraction Buffer
- 15ml Hybridization Buffer with Biotinylated Oligo(dT) Probe
- 15ml Blocking Particles, 0.04 micron carboxylated, yellow dyed, polystyrene particles
- 20 • 20ml Streptavidin MagneSphere<sup>®</sup> Paramagnetic Particles available from Promega Corporation
- 150ml PolyATtract Wash Solution [SSC, 0.5X Solution]
- 25ml Nuclease-Free Water
- 6 96 Well V-Bottom Plates
- 6 48 Well GeNunc<sup>™</sup> Modules
- 25 • 2 GeNunc<sup>™</sup> Frames
- 2 GeNunc<sup>™</sup> Frame Supports
- 3 Plate Sealers
- 24 Strip-Ease<sup>®</sup> PCR Tube Caps

30 The above materials are available from Promega Corporation, Madison, Wisconsin, U.S.A.

GeNunc frames and frame supports are commercially available from the Nunc Inc. located in Naperville, Illinois, U.S.A. Strip-ease PCR tube caps are commercially available from the Robbins Scientific Corporation located in Sunnyvale, California, U.S.A.

35 Utilizing the above components, the following steps were performed:

-15-

1. GTC extraction buffer was added to tissue, e.g., mouse liver lysate, at a ratio of 20  $\mu$ l per 2.5 mg (or less) of tissue or 20  $\mu$ l per  $1 \times 10^5$  (or less) tissue culture cells.

2. The mixture of step 1 was homogenized using a Polytron Homogenizer, Brinkmann Instruments, Westbury, New York.

3. 20  $\mu$ l of each sample was transferred to a well. For example, 96 such 20  $\mu$ l samples are transferred in a typical application of the present invention.

4. 40  $\mu$ l of prewarmed (e.g., to 70°C) hybridization buffer comprising biotinylated oligo (dT) probe was added per well and incubated at room temperature for five minutes.

5. 35  $\mu$ l of blocking or masking particles were added per well, the plate was sealed, and centrifuged for ten minutes at room temperature. The centrifugation step should be accomplished at approximately 1,700xg. This centrifugation step traps precipitated proteins and insoluble cell material underneath the pellet of blocking particles.

At this point, a typical sample will contain (proceeding from the bottom of the centrifuge tube) a pellet or collection of cell debris covered by a pellet or layer of masking or blocking particles. Lastly, above the pellet of blocking particles is cleared cell lysate comprising mRNA target particles dispersed in the medium, i.e., buffer.

Referring now to FIG. 1, shown in expanded perspective view, is one titer well 10 of what would be an extended array, e.g., 96, of such wells. Well 10 appears as it would subsequent to centrifugation step 5 above. Within well 10 is cell debris and precipitated proteins in the form of a pellet 12. Covering pellet 12 is a layer of blocking particles 14. Over layer 14 is cleared cell lysate 16. Cleared cell lysate 16 contains mRNA which, in further processing, will be separated from the buffer medium. Blocking particle layer 14 comprises 0.04 micron carboxylated polystyrene particles (i.e., a latex). A sufficient quantity of such

-16-

particles is added to create layer 14 which separates cleared cell lysate 16 from cell debris 12. Prior to the present invention, in order to prevent interference between cell debris 12 and a target substance in lysate 16, it would have been necessary for cleared lysate 16 to be removed from cell 10 to a clean reaction chamber. It is elimination of this procedure which is one of the primary advantages of the present invention. Lysate 16 protected from debris 12 by layer 14 may now be exposed to subsequent processing steps, e.g., magnetic separation, resulting in the collection of target substance, e.g., mRNA, therefrom.

Further, the width of layer 14 may be adjusted by changing the quantity of particles 14, thereby changing liquid level 18 (assuming a fixed quantity of liquid). The ability to adjust liquid level 18 by adjusting the quantity of blocking particles 14 is potentially a useful tool for automating isolation/transcription/amplification processes.

6. 60  $\mu$ l of SA-PMPs were added to each well and incubated at room temperature for two minutes.

### Example 2

The pin array of a magnetic separator described in the above-cited concurrently filed application was treated in 0.5 M sodium hydroxide for one minute before use. The pins were then rinsed with sterile H<sub>2</sub>O.

### Example 3 mRNA Purification

The array of wells generated in Example 1 was then placed into the base of a multiple pin/magnetic separator as described in the above-referenced, concurrently filed application. The hinges of the pin plate were positioned in the hinge channels of the base and the pin plate was carefully lowered into the Microtiter™ plate. The external magnet pack was then placed on the pin plate, contacting the pin ends and the admixtures were incubated until the magnetic particles were cleared from the lysate, typically about 90 sec.

-17-

The pin plate and magnet were then raised to a 45° angle, and the Microtiter™ plate containing the cell lysates was replaced with a fresh plate containing 155 µl of 0.5x SSC 10 µg/ml BSA in each well. The magnet pack was removed and the attached particles were released to wash by raising and lowering the pin plate. The particles were recaptured by placing the magnet pack in contact with the pins. The release and recapture steps were repeated for a total of two washes of the SA-PMP complexes. The rinse Microtiter™ plate was then removed and replaced with a GeNunc plate containing 20 µl of dH<sub>2</sub>O in each well. The pin plate and magnet were lowered so that the pins were immersed. The magnet was removed and the particles were released in nuclease free water and recaptured, releasing the mRNA into solution. After 1 min, the magnet was returned to position atop the pin plate and collected the particles on the pins, typically about 90 sec. The remaining water medium contained purified mRNA.

#### Example 4

The purified isolated mRNA generated in Example 3 was used to synthesize cDNA by adding 10µl Reverse Transcriptase Master Mix, components commercially available from Promega Corporation, Madison, Wisconsin, U.S.A., to the wells and incubating the mixture at 37°C for 30 minutes followed by heat inactivation for 5 minutes at 95°C.

In summary, the present invention provides a simple, cost-effective, efficient, high throughput method for effective separation of multiple small samples and facilitating processing steps, especially the magnetic particle-ligand complex.

#### Example 5

In this example, carboxylated polystyrene latex blocking particles colored with fluorescent yellow dye were used. Such particles are commercially available from Magsphere Inc., Pasadena, California,

-18-

U.S.A. The particles had a size of about 0.043  $\mu\text{m}$  and comprise a yellow color water-based latex with about 10% dyed polymer particles in water medium on a weight per unit volume basis. The yellow color is used primarily to identify the presence of the particles during the processing steps.

Aggressive centrifugation of the water-based latex blocking particles, substantially as purchased, produced no precipitate or agglomerate. Under observation in a micro fluoroscope, the substantially independent particles appear to float in the aqueous medium, apparently being subject to Brownian movement.

The blocking particles have been found to create agglomerates, aggregates, clusters, or "flocs" which are capable of centrifugation, as follows:

Two ml of stock carboxylated polystyrene latex particles were placed in a centrifuge tube. Six ml of GTC Extraction Buffer was added to the tube and next, 12 ml of dilution buffer which has been heated to 70 degrees C. GTC extraction buffer is commercially available from Promega Corporation under the trade name PolyATtract® and comprises: 4M guanidine thiocyanate, 25mM sodium citrate, and 2%  $\beta$ -mercaptoethanol. The dilution buffer comprises 0.01M Tris-HCl, pH 7.5, 6 X SSC, 0.24% sodium dodecyl sulfate (SDS), 0.001 M EDTA, and 1% beta-mercaptoethanol (BME). The materials are mixed and centrifuged at 1,700 X G for ten minutes. Under fluorescent microscopy, the resulting agglomerates are sheetlike. The particles did not evidence Brownian motion. Even though only about 2 ml of particles was employed in the process, their packed volume after agglomeration and centrifugation is approximately 5 ml.

#### Example 6

In this example, spherically-shaped agglomerates or coagulants were created.



-19-

5 GTC extraction buffer and dilution buffer, in the amounts indicated in Example 5, were first mixed together. Two ml of stock masking particles were then added to the premixed buffers. After mixing and centrifuging the mixture, as described in Example 5, the agglomerates appeared to be substantially spherical under fluorescence microscopy.

#### Example 7

10 Individual mixtures of 2 ml of stock particles and the quantities of Tris, SDS solution, 6 X SSC solution and EDTA solution indicated in Example 5 were prepared. After mixing and centrifugation under the conditions indicated in Example 5, no agglomerates or precipitate was generated. From this it was concluded that all the above buffer components had to be present for the desired agglomeration reaction to occur.

#### Example 8

15 This example involves the collection by agglomeration of colloidal-dimension magnetic particles that could not otherwise be collected using conventional, low magnetic strength separation techniques.

20 In this example, magnetically responsive particles of less than one micron major diameter would be used. Particles to which this aspect of the invention applies are described in U.S. 5,200,084 to Liberti et al., at column 2 lines 65 - 68, and are apparently discussed in U.S. patent application Ser. No. 389,697 filed August 4, 1989, which application is referred to at column 3, lines 35, 41. Both the above excerpts from the '084 Liberti et al. patent, and the references cited in those excerpts, are incorporated by reference herein. Magnetically responsive particles of that dimension would be of true colloidal dimension and would not be removed from solution or suspension by conventional centrifugation. In this example, submicron magnetically responsive particles would be mixed with GTC buffer, and dilution buffer in ratios substantially as

25

-20-

disclosed in Example 5. Agglomeration is permitted to occur generating particles of a supra micron (i.e., above 1 micron), non-colloidal major dimension. These substantially larger particles may be separated from the medium in which they were dispersed by centrifugation or by application of relatively low magnetic fields.

**Example 9**

The compositions of buffers and solutions referred to herein are as follows:

**1X PBS, pH 7.4:**

10           0.2g/L KCl  
             8.0g/L NaCl  
             0.2g/L  $\text{KH}_2\text{PO}_4$   
             1.15g/L  $\text{Na}_2\text{HPO}_4$

**PolyATtract® GTC Extraction Buffer:**

15           4M guanidine thiocyanate  
             25mM sodium citrate  
             2%  $\beta$ -mercaptoethanol

**PolyATtract® Wash Solution:**

20           7.5mM sodium citrate  
             75mM NaCl  
             10 $\mu$ g/ml bovine serum albumin (BSA)

**Hybridization Buffer with Biotinylated Oligo(dT) Probe:**

25           10mM Tris-HCl, pH 7.1  
             90mM sodium citrate  
             900mM NaCl  
             1mM EDTA  
             0.25% SDS  
             1%  $\beta$ -mercaptoethanol  
             75nM Biotinylated Oligo(dT) Probe

-21-

## RT 9600 Gold Buffer:

5           40mM Tris-HCl, pH 8.3  
          202mM KCl  
          6mM MgCl<sub>2</sub>  
          8mM DTT  
          2.7% yellow dye

## 20 X SCC:

10           3.0M sodium chloride  
          0.3M sodium citrate  
          pH adjusted to 7.0 with NaOH.

Example 10

15           Messenger RNA, purified from 2-fold serially diluted Mouse Liver  
          Lysate, as described above, was reverse transcribed and amplified by  
          PCR for detection of a rare cytokine mRNA, IL-1 $\beta$ . Amplification was  
          performed using Taq DNA Polymerase from Boehringer Mannheim  
          according to their specifications for PCR conditions. Five microliters of  
          each 30 $\mu$ l cDNA sample were amplified in a 50 $\mu$ l PCR reaction  
          containing 1 $\mu$ M of each primer. Twenty microliters of each PCR  
20           reaction were analyzed on a 2% agarose gel and stained with ethidium  
          bromide. Each 20 $\mu$ l sample corresponds to 1/15 of the original tissue  
          or cell sample. RT-PCR product was faintly detected at the lowest level  
          of starting material.

25           While the present invention has now been described and  
          exemplified with some specificity, those skilled in the art will appreciate  
          the various modifications, including variations, additions, and omissions,  
          that may be made in what has been described. Accordingly, it is  
          intended that these modifications also be encompassed by the present  
          invention and that the scope of the present invention be limited solely  
          by the broadest interpretation that lawfully can be accorded the  
30           appended claims.

-22-

**CLAIMS:**

What is claimed is as follows:

1. A method of agglomerating colloidal particles in an aqueous medium, the method comprising the steps of:
  - 5 providing a quantity of particles of colloidal dimension in an aqueous medium;
  - providing a GTC buffer;
  - providing a dilution buffer;
  - 10 mixing the GTC buffer, the dilution buffer and the colloidal particles to cause the colloidal particles to agglomerate into particles substantially larger than particles of colloidal dimension and which can be centrifuged from the medium.
2. A method according to claim 1 wherein the particles have a major dimension in the range of about 1 millimicron to about 1 micron.
- 15 3. A method according to claim 1 wherein the GTC buffer and the dilution buffer are first mixed together, and the particles are thereafter added and mixed with the buffer mixture resulting in the production of agglomerates.
- 20 4. A method according to claim 1 wherein the GTC buffer, the dilution buffer and the particles are mixed in the presence of cell lysate which is relatively denser than said particles, agglomeration is allowed to occur, and the agglomerates are centrifuged onto the cell lysate thereby creating a blocking layer thereover.
- 25 5. A method according to claim 4 wherein the cell lysate is generated in a process of purifying detection of biological target particles selected from the group consisting of DNA, RNA or proteins.

-23-

6. A method according to claim 1 wherein the GTC buffer is mixed with the masking particles and the dilution buffer is thereafter added to create the agglomerates.

5 7. A method according to claim 1 wherein the masking particles are magnetically responsive colloidal magnetite.

8. A method according to claim 7 wherein the magnetic masking particles have a major dimension of less than one micron.

10 9. A method according to claim 1 wherein the agglomerates have a major dimension of at least one micron and can be separated from the medium by low magnetic field separation devices.

10. A method according to claim 1 wherein the agglomerates have a major dimension of at least one micron and can be separated from the medium by centrifugation.

15 11. A method according to claim 1 wherein particles having a major dimension of less than 1 micron are used and the method further includes the step of performing an immunoassay.

12. A method according to claim 1 wherein the GTC buffer comprises guanidine diocynate, sodium citrate, and beta-mercaptoethanol.

20 13. A method according to claim 1 wherein the dilution buffer comprises tris-HCl, sodium dodecyl sulfate, SSC, and EDTA.

14. A method of agglomerating colloidal particles in an aqueous medium, the method comprising the steps of:

-24-

providing a quantity of particles of colloidal dimension in an aqueous medium;

providing a chaotropic agent;

5       mixing the chaotropic agent and the colloidal particles to cause the colloidal particles to agglomerate into particles substantially larger than particles of colloidal dimension and which can be centrifuged from the medium.

15.    A method according to claim 14 wherein the particles have a major dimension in the range of about 1 millimicron to about 1 micron.

10       16.   A method according to claim 14 wherein the chaotropic agent comprises a GTC buffer and a dilution buffer.

15       17.   A method according to claim 16 wherein the GTC buffer, the dilution buffer and the particles are mixed in the presence of cell lysate which is relatively denser than said particles, agglomeration is allowed to occur, and the agglomerates are centrifuged onto the cell lysate thereby creating a blocking layer thereover.

18.    A method according to claim 17 wherein the cell lysate is generated in a process of purifying detection of biological target particles selected from the group consisting of DNA, RNA or proteins.

20       19.   A method according to claim 14 wherein the GTC buffer is mixed with the colloidal particles and the dilution buffer is thereafter added to create the agglomerates.

20.    A method according to claim 14 wherein the colloidal particles are magnetically responsive colloidal magnetite.



-25-

21. A method according to claim 20 wherein the magnetic masking particles have a major dimension of less than one micron.

22. A method according to claim 14 wherein the agglomerates have a major dimension of at least one micron and can be separated from the medium by low magnetic field separation devices.

5

23. A method according to claim 14 wherein the agglomerates have a major dimension of at least one micron and can be separated from the medium by centrifugation.

1/1




FIG. 1

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/11831

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 21/00, 21/02; C12N 15/10; C12P 19/34

US CL : 536/25.4, 25,42; 435/91.4, 91.3

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/25.4, 25,42; 435/91.4, 91.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NoneElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
APS and CAS: RNA purification, guanidine isothiocyanate, magnetic particles, masking particles, blocking particles

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Analytical Biochemistry, Volume 162, issued 1987, Chomczynski et al., "Single-Step Method of RNA Isolation by Acid Guanidium Thiocyanate-Phenol-Chloroform Extraction", pages 156-159, see entire abstract and introduction.	1-23
A	Biochemistry, Volume 18, No. 24, issued 1979, Chirgwin et al., "Isolation of Biological Active Ribonucleic Acid from Sources Enriched in Ribonuclease", pages 5294-5299, see abstract and introduction.	1-23
A, E	US, A, 5,459,253 (WOLIN ET AL.) 17 October 1995, see abstract and claims.	1-23
A	US, A, 5,108,933 (LIBERTI ET AL.) 28 April 1992, see abstract and claims.	1-23

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

20 DECEMBER 1995

Date of mailing of the international search report

17 JAN 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

GARY L. KUNZ

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/11831

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 5,200,084 (LIBERTI ET AL.) 06 April 1993, see abstract and claims.	1-23
A	US, A, 4,988,618 (LI ET AL.) 29 January 1991, see abstract and claims.	1-23